MERZ PHARMACEUTICALS GMBH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1908-01-01

Employees: 101

Market Cap: -

Website: https://www.radiesse.de

Clinical Trials

A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods

Phase 1

Completed

Conditions: N/A, as no Specific Medical Condition Will be Treated

Interventions: Drug: IncobotulinumtoxinA

First Posted Date: 2022-10-18

Last Posted Date: 2023-06-22

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 40

Registration Number: NCT05585398

Locations: 🇩🇪
Merz Investigational Site #0490385, Hamburg, Germany

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Phase 2

Completed

Conditions: Essential Tremor of the Upper Limb

Interventions: Drug: NT 201
Drug: Placebo

First Posted Date: 2021-02-23

Last Posted Date: 2024-04-22

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 78

Registration Number: NCT04766723

Locations: 🇺🇸
Mount Sinai Medical Center, Merz Investigational Site #0010191, New York, New York, United States
🇺🇸
Medstar Georgetown Neurology, Merz Investigational Site #0010231, McLean, Virginia, United States
🇨🇦
London Health Sciences Centre, Merz Investigational Site #0010087, London, Ontario, Canada

and more 11 locations

Post-Market Clinical Follow-up Performance and Safety Study of Etermis 3 and 4 in the Face

Completed

Conditions: Facial Volume Enhancement
Correction of Facial Wrinkles/Folds

First Posted Date: 2019-12-24

Last Posted Date: 2020-01-02

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 154

Registration Number: NCT04210258

Locations: 🇩🇪
Merz Investigational Site #0490099, Darmstadt, Germany
🇩🇪
Merz Investigational Site #0490095, Hamburg, Germany
🇩🇪
Merz Investigational Site #0490345, Hamburg, Germany

and more 3 locations

Study to Compare the Efficacy and Safety of NT 201 (botulinum Toxin) with Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Phase 3

Recruiting

Conditions: Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

Interventions: Drug: NT 201
Drug: Placebo

First Posted Date: 2019-06-20

Last Posted Date: 2024-12-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 600

Registration Number: NCT03992404

Locations: 🇺🇸
Brooks Rehabilitation Clinical Integration and Research, Merz investigational site #0010483, Jacksonville, Florida, United States
🇺🇸
Physical Medicine and Rehabilitation at University of Alabama at Birmingham; Merz investigational site #0010479, Birmingham, Alabama, United States
🇺🇸
University of Arkansas for Medical Sciences, Merz investigational site #0010481, Little Rock, Arkansas, United States

and more 78 locations

Local Study of Akatinol Memantine in VaD in Russia

Phase 3

Completed

Conditions: Vascular Dementia

Interventions: Drug: Akatinol Memantine 10 mg
Drug: Akatinol Memantine 20 mg

First Posted Date: 2019-06-14

Last Posted Date: 2022-07-22

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 130

Registration Number: NCT03986424

Locations: 🇷🇺
Federal state budgetary military educational institution of higher education "Military Medical Academy named after S.M. Kirov" of the Ministry of defence of the Russian Federation, Sankt-Peterburg, Russian Federation
🇷🇺
Scientific Research Institute of Neurology, Merz Investigational Site #0070008, Moscow, Russian Federation
🇷🇺
Federal State Autonomous Institution of Higher Learning "Peoples' Friendship University of Russia", Medical Institute, Moscow, Russian Federation

and more 1 locations

Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation

Not Applicable

Completed

Conditions: Subjects Desiring Lip Augmentation

Interventions: Device: Etermis 4®

First Posted Date: 2017-08-22

Last Posted Date: 2018-05-23

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 75

Registration Number: NCT03256942

Locations: 🇩🇪
Dermatologische Praxis, Merz Investigational Site #0490345, Hamburg, Hanse Stadt Hamburg, Germany
🇩🇪
Universität Hamburg, FB Chemie und Molekularbiologie, Merz Investigational Site #0490095, Hamburg, Germany
🇩🇪
DRK Kliniken Nordhessen, Merz Investigational Site #0490309, Kassel, Hessen, Germany

and more 3 locations

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

Phase 3

Completed

Conditions: Chronic Troublesome Sialorrhea
Stroke
Traumatic Brain Injury
Intellectual Disability
Cerebral Palsy

Interventions: Drug: NT 201 Placebo
Drug: NT 201

First Posted Date: 2014-10-21

Last Posted Date: 2021-08-10

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 256

Registration Number: NCT02270736

Locations: 🇬🇪
Merz Investigational Site #9950001, Tbilisi, Georgia
🇺🇦
Merz Investigational Site #3800001, Dnipropetrovsk, Ukraine
🇺🇦
Merz Investigational site #3800003, Odesa, Ukraine

and more 28 locations

Botulinum Toxin A to Treat Arm Tremor

Phase 2

Completed

Conditions: Essential Tremor of the Upper Limbs

Interventions: Drug: IncobotulinumtoxinA
Drug: Placebo

First Posted Date: 2014-08-04

Last Posted Date: 2021-02-18

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 30

Registration Number: NCT02207946

Locations: 🇺🇸
Merz Investigational Site #0010191, New York, New York, United States
🇨🇦
Merz Investigational Site #0010317, Winnipeg, Manitoba, Canada
🇨🇦
Merz Investigational Site #0010089, Halifax, Nova Scotia, Canada

and more 3 locations

Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy

Phase 2

Completed

Conditions: Spastic Paraplegia and Hemiparesis
Equine and Equinovarus Foot Deformation
Cerebral Palsy

Interventions: Drug: Botox®
Drug: Xeomin

First Posted Date: 2014-07-11

Last Posted Date: 2017-01-26

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 64

Registration Number: NCT02188277

Locations: 🇷🇺
Federal State Budget Educational Institution of Higher Professional Learning "Stavropol State Medical University" of the Ministry of Health of the Russian Federation, Stavropol, Russian Federation
🇷🇺
Federal State Autonomous Institution "Scientific Center of Children's Health" of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
🇷🇺
State Budget Institution of Health in Moscow "Scientific and Practical Center of Pediatric psychoneurology Moscow Health Department", Moscow, Russian Federation

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Phase 3

Completed

Conditions: Chronic Troublesome Sialorrhea
Post-stroke
Traumatic Brain Injury
Parkinson's Disease

Interventions: Drug: IncobotulinumtoxinA (75 Units)
Drug: IncobotulinumtoxinA (100 Units)
Drug: Placebo

First Posted Date: 2014-03-19

Last Posted Date: 2018-03-27

Lead Sponsor: Merz Pharmaceuticals GmbH

Target Recruit Count: 184

Registration Number: NCT02091739

Locations: 🇩🇪
Merz investigational site #049172, Bonn, Germany
🇩🇪
Merz Investigational Site #049335, Gera, Germany
🇩🇪
Merz Investigational Site #049337, Haag i.OB, Germany

and more 28 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy